MedTrace Logo

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

NCT00268528 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 720

Last updated 2020-07-07

No results posted yet for this study

Summary

This clinical trial is assessing compliance with long-term mercaptopurine treatment in young patients with acute lymphoblastic leukemia in remission. Assessing why young patients who have acute lymphoblastic leukemia may not take their medications as prescribed may help identify ways to assist them in taking their medications more consistently and may improve long-term treatment outcomes.

Conditions

  • Childhood Acute Lymphoblastic Leukemia in Remission

Interventions

BEHAVIORAL

Compliance Monitoring

Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mercaptopurine

Given PO

DRUG

Methotrexate

Given PO

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Study of Socioeconomic and Demographic Variables

Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Smita Bhatia · Children's Oncology Group

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-30
Primary Completion
2012-03-05
Completion
2020-06-30

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268528 on ClinicalTrials.gov